Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGender-Affirming CareBlue Shield CA Camcevi Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Shield of CaliforniaPolicy N/A

    Leuprolide Mesylate (Camcevi) Coverage for Adolescent Gender Dysphoria

    Customize your policy alerts

    Sign up for all blue_shield_of_california policy alerts

    Know when blue_shield_of_california releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial medical benefit drug policy governing coverage and prior authorization requirements for leuprolide mesylate (Camcevi) administered for gender dysphoria in adolescents.

    Policy Summary
    PayerBlue Shield of California
    PolicyLeuprolide Mesylate (Camcevi) Coverage for Adolescent Gender Dysphoria
    Policy CodePolicy N/A
    Change TypeDiagnosis code update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit office chart notes, laboratory results, or other clinical information demonstrating that the member meets all applicable medical-necessity requirements.
    SourceLink
    POLICY UPDATE CHANGES

    ICD-10 code F64.0 was added to the policy diagnosis code list.

    42 mgMaximum covered dose per administration
    Every 6 monthsMaximum covered administration frequency
    J1952Assigned HCPCS code for Camcevi
    4Listed ICD-10 diagnosis codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    42 mg syringe
    Product strength and presentation

    Coverage Criteria

    Gender Dysphoria in Adolescents

    Covered without prior authorization or preservice review when all applicable parameters are met; otherwise prior authorization or preservice review is required.

    Gender dysphoria in adolescents

    • The member has gender dysphoria in adolescence as the condition being treated.

      Gender Dysphoria in Adolescents is the condition listed in the policy.

    • The request is associated with one of the following ICD-10 diagnosis codes: F64.0, F64.1, F64.2, or F64.9.
    • The administered dose does not exceed 42 mg of leuprolide subcutaneously once every 6 months.42 mg subcutaneously once every 6 months

    Conditions not listed in this policy are not covered under the condition-specific parameters listed here and require a separate medical-necessity review. For off-label uses, the requirements of California Health and Safety Code section 1367.21 must also be met.

    Coding and Dose Parameters

    HCPCSHCPCSCovered
    J1952Leuprolide injectable, camcevi, 1 mg
    ICD-10ICD-10Covered
    F64.0
    F64.1
    F64.2
    F64.9
    Covered dose and frequency
    Maximum covered dose42 mg leuprolide
    Route of administrationSubcutaneous
    Maximum frequencyOnce every 6 months

    Provider Submission and Billing Actions

    Note

    No Authorization When All Parameters Are Met

    For Gender Dysphoria in Adolescents, no Prior Authorization or Preservice Review is required when all listed policy parameters are met. Coverage applies when the covered dose and qualifying ICD-10 diagnosis requirements are satisfied.

    • Dose: no more than 42 mg leuprolide subcutaneously once every 6 months.
    • Qualifying ICD-10 codes: F64.0, F64.1, F64.2, or F64.9.
    Note

    Submit Requests Through CarePro

    For PPO, Direct Contract HMO, and, when applicable, ASO and Shared Advantage, submit applicable requests through Evolent's CarePro Provider Portal.

    Documentation Required

    Product Background

    Camcevi is leuprolide mesylate, a gonadotropin-releasing hormone (GnRH) agonist in the antineoplastic drug category. This commercial medical benefit policy addresses coverage for Camcevi when used for gender dysphoria in adolescents and establishes the applicable coverage criteria.

    Definitions

    Mechanism of action
    Mechanism of actionGonadotropin-releasing hormone (GnRH) agonist
    Policy Summary
    PayerBlue Shield of California
    PolicyLeuprolide Mesylate (Camcevi) Coverage for Adolescent Gender Dysphoria
    Policy CodePolicy N/A
    Change TypeDiagnosis code update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit office chart notes, laboratory results, or other clinical information demonstrating that the member meets all applicable medical-necessity requirements.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dose ParametersProvider Submission and Billing ActionsProduct BackgroundDefinitions

    Provide Medical-Necessity Documentation

    Submit clinical documentation demonstrating that the member meets all applicable medical-necessity requirements.

    • Include office chart notes, laboratory results, or other relevant clinical information.
    Billing Rule

    Use the Assigned HCPCS Code and NDC

    For billing, submit the drug using the assigned HCPCS code listed in the drug policy together with the corresponding NDC (National Drug Code).

    • Do not use an unlisted, unspecified, or miscellaneous billing code when a specific HCPCS code is assigned to the drug.
    • The HCPCS code and NDC must correspond to the billed drug.
    Prior Authorization

    Authorization Required When Parameters Are Not Met

    If any listed policy parameter is not met, Prior Authorization or Preservice Review is required before the applicable service or drug is provided.

    • This includes exceeding the covered dose or using a diagnosis code outside the listed qualifying ICD-10 codes.
    Denial Risk

    Incorrect Code or Missing NDC May Result in Denial

    Claims may be denied or rejected when the assigned HCPCS code or required corresponding NDC is missing, incorrect, or replaced with an unlisted, unspecified, or miscellaneous code.

    • Verify that the submitted HCPCS code is the specific code assigned to the drug in the policy.
    • Include the corresponding NDC with the HCPCS code.